Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following in
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following in
An investigator-initiated Phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor-infiltrating lymphocyte (TIL) therapy.